Closed & Collaborative – January to February 2026

The opening months of 2026 painted a vivid picture of a life sciences sector in rapid motion, stretched between scientific ambition and operational pragmatism, and increasingly defined by partnerships that dissolve long-standing boundaries between discovery disciplines, technology domains, and global health mandates.

While pharmaphorum reported directly on such deals as GSK’s agreement to buy Canada's 35Pharma and its drug candidate for pulmonary hypertension (PH) for $950 million, what emerged more generally from January and February this year was not a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

From AI-native drug discovery to oral biologics, from epidemic‑readiness to digitised clinical trials, from surfaceome-guided oncology to the quiet, but essential, machinery that keeps advanced therapies and hospital finances moving – the first two months of the year felt less like a transactional season and more like a reflection of an industry in structural transition.

AI grows up: From pilots to platform‑scale commitments

It can arguably be said that what was once framed as experimental has now become foundational. Nowhere was this more visible than in the escalating maturity of AI partnerships. Servier’s €1bn+ multi‑target alliance with Iktosprovided one of the clearest signals yet that large pharma is no longer dabbling. Instead, Servier is weaving Iktos’ generative design and robotics-driven discovery directly into its oncology and neurology pipelines – a shift from occasional target-specific projects to portfolio‑level integration.

Similarly, Eli Lilly’s deepening collaboration with Nimbus Therapeutics shows how AI-enhanced computational chemistry has become central to competitive positioning in metabolic disease. The new multi‑year agreement to develop an oral obesity therapy, structured with $55m upfront and up to $1.3bn in milestones, follows earlier success in their AMPK program and underscores how AI-first design is now a validated strategic feeder for big therapeutic franchises.

On the clinical insight side of the value chain, meanwhile, SOPHiA GENETICS’ partnership with MD Anderson demonstrates how AI-driven analytics and NGS interpretation are beginning to shape not only research, but also global access to world-class oncology testing. MD Anderson’s ambition to extend its innovations far beyond the walls of Houston now rests partly on SOPHiA’s ability to operationalise data-driven medicine across 800 institutions in 70 countries.

Taken together, these deals reveal an unmistakable drift: AI is no longer “adjacent”; rather, it is becoming infrastructural, embedded across discovery, translational analytics, and real‑world clinical decision-making.

Oncology widens its lens with next‑generation targets and biomarkers

If AI provided the connective tissue of early 2026, oncology provided much of its narrative momentum. Amgen’s global licensing deal with DISCO Pharmaceuticals, worth up to $618m, is notable not simply for its size, but for its scientific premise. DISCO’s surfaceome mapping platform identifies otherwise inaccessible cancer cell‑surface targets, enabling Amgen to pursue novel bispecific ADCs and T‑cell engagers in notoriously difficult indications such as SCLC and MSS‑CRC. It is a partnership rooted in the belief that new target space is still out there, if one knows how to look for it.

A different frontier emerged in STORM Therapeutics’ strategic collaboration with Alida Biosciences. With this, cancer drug development is being reimagined through the lens of epitranscriptomics, as both companies work to correlate transcript‑specific m6A RNA modifications with clinical response to STC‑15, the first METTL3 inhibitor to enter human trials. It is quietly radical: a biomarker paradigm built not on DNA or proteins, but on RNA modifications themselves.

Meanwhile, Lonza’s Synaffix unit and Sidewinder Therapeutics offered another reminder that ADCs continue to evolve, their multi‑target license bringing bispecific ADCs – designed for enhanced tumour‑cell internalization – closer to clinical reality, marrying Sidewinder’s precision antibodies with Synaffix’s validated conjugation chemistry.

Even in bladder cancer, innovation took a combinatorial turn. Ferring and Theralase agreed to explore the pairing of Ruvidar, a light‑activated small molecule, with Ferring’s FDA‑approved ADSTILADRIN gene therapy for BCG‑unresponsive NMIBC. Adding this new cohort to an ongoing clinical study reflects a growing confidence that therapeutic complementarities, even between modalities as different as photodynamic agents and adenoviral vectors, may unlock breakthroughs in otherwise recalcitrant disease.

Epidemic preparedness becomes operational

If the oncology story was about depth, the infectious disease story was about speed. In collaboration with CEPI, the University of Oxford and the Serum Institute of India executed one of the fastest vaccine mobilisation efforts seen outside COVID‑19, manufacturing up to 100,000 investigational doses of the ChAdOx1 RVF vaccine for Rift Valley fever. With an initial 10,000 doses reserved for trials in outbreak zones of Senegal and Mauritania, the partnership models what epidemic-readiness looks like when academic science, manufacturing capacity, and global health financing align without hesitation.

Elsewhere, a different flavour of preparedness emerged in Circio’s collaboration with the University of Texas Medical Branch. By deploying its circVec circular RNA constructs – capable of driving protein expression for months – the partnership aims to explore long‑term passive protection against high‑risk viral pathogens. It positions circular RNA not merely as a gene therapy modality, but as a future tool for outbreak control.

Clinical development grows more participant‑centric

Beyond therapeutics, early 2026 also brought forwards a wave of collaborations focused on reducing friction in clinical operations. Kayentis’ partnership with Ametris (formerly ActiGraph) represented one of the clearest attempts yet to integrate wearable adherence directly into the eCOA experience. By embedding real-time wear‑time monitoring and automated device synchronisation, the pair aim to address one of the thorniest issues in digital trials: the gap between device provision and device use.

At the same time, SEQSTER’s expanded work with Praxis Precision Medicines reflects a broader movement to treat real‑world data not as an observational add‑on, but as a structural asset capable of accelerating screening, enrolment, and longitudinal follow‑up. In CNS disorders, where disease trajectories are complex and phenotypes varied, these capabilities are becoming essential.

The invisible infrastructure of life sciences gets its due

One of the quieter shifts during this period was the consolidation of operational infrastructure supporting advanced therapies, specialty care, and even community pharmacy. Title21’s acquisition of MyCellHub, a Belgian MES developer, expanded its existing quality and orchestration suite into a genuine end‑to‑end digital backbone for cell and gene therapy manufacturing. For a sector long hamstrung by manual GMP processes, the deal points to an accelerating harmonisation of ATMP production.

In US healthcare operations, EnableComp’s purchase of H/ROI strengthened its authority in the most complex corner of revenue cycle management: clinical denials and DRG validation. Against intensifying payer scrutiny and eroding margins, these capabilities have become mission‑critical for health systems trying to stay solvent while delivering high‑acuity care.

And in the UK, the acquisition of 68 Jhoots Pharmacy sites by Allied Pharmacies represented an important stabilising move for frontline healthcare access. With many sites temporarily closed before the transaction, Allied’s commitment to reinstating services underscores how M&A can serve not only commercial consolidation, but also community continuity.

Reformulating access: Oral biologics and compassionate distribution

Alongside these operational shifts ran a quieter theme centred on patient access and administration innovation. The Eurostars‑funded collaboration between Bio‑Sourcing and Zerion, aimed at developing a first‑of‑its‑kind oral trastuzumab using the BioMilk and Dispersome platforms, offers a provocative reimagining of monoclonal antibody delivery. For HER2‑positive breast cancer, an oral agent could radically expand flexibility for patients and reduce dependence on infusion centres by the end of the decade.

Meanwhile, Cycle Pharmaceuticals and Inceptua extended the NITYR Free Goods Programme to Morocco and Egypt, bringing treatment for HT‑1 and AKU to populations otherwise unable to access it. The commitment to maintain supply over patients’ lifetimes stands out in a period when global inequity in rare disease care remains profound.

Genomics matures into clinical infrastructure

Finally, two collaborations showcased how long‑read sequencing is moving from research novelty into clinical necessity. PacBio’s partnership with UW Medicine and Seattle Children’s positions HiFi whole‑genome sequencing as the first‑line assay to investigate Sudden Unexplained Death in Childhood across 200 family trios – an ambitious attempt to consolidate multi‑test diagnostic odysseys into a single, sensitive workflow.

In parallel, PacBio’s planned work with the n‑Lorem Foundation and EspeRare folds long‑read data directly into the design and molecular validation of n‑of‑1 antisense therapies for ultra‑rare disease. When every nucleotide matters – repeats, structural variants, regulatory elements – complete genomic resolution becomes a prerequisite for viable therapy development, rather than a luxury.

What these two months tell us

Across this unusually dense period of dealmaking, three overarching dynamics stand out. First, AI is no longer an experiment, but an integrated architecture, shaping how targets are identified, molecules are designed, and clinical signals are interpreted. Secondly, modalities are converging: surfaceome‑derived targets meet next‑gen ADCs; RNA modification inhibitors meet epitranscriptomic biomarkers; gene therapy meets photodynamic oncology. And third, the industry is becoming increasingly aware that innovation demands infrastructure, whether manufacturing execution for cell therapies, data-rich digital trial environments, or simply open pharmacy doors for the communities that rely on them.

If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that collaboration is not a choice, but a condition of progress – and that the deals that matter most are those that weave discovery, delivery, and access into one coherent arc.

Editor’s note: This round‑up is based on press releases and company communications received in January and February 2026.